Win One/ Lose One: Latest Rulings in the IP Battles Over CRISPR/Cas9

On March 28, the latest round in the intellectual property battle over CRISPR/Cas9 ended with the European Patent Office (EPO) ruling in favor of the University of California / University of Vienna, the work of scientists Jennifer Doudna and Emmanuelle… Read »

Reflecting on AACR

The American Association for Cancer Research annual meeting is always a source of major news and discussion on the oncology research front, and the 2017 meeting held earlier this month was no exception.   One area of particular interest was… Read »

PARP Inhibitors Chalk Up Impressive Gains in Ovarian Cancer Maintenance Therapy

On March 27, the FDA gave Tesaro a broad approval for its PARP inhibitor, niraparib, as maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after a complete or partial response to platinum-based chemotherapy. The… Read »

National Academies of Science and Medicine Cautiously Endorse Some Germline Gene Editing — In the Future

In February the National Academy of Sciences and the National Academy of Medicine issued a new report on the technical, social and regulatory concerns surrounding gene editing, entitled, “Human Genome Editing: Science, Ethics, and Governance.” Authored by a 22… Read »

Alzheimer’s Disease Part Three: Meeting 2025 Goals

In early 2011, the National Alzheimer’s Project was formed — a strategic plan aimed at addressing the looming health care crisis posed by the disease and the aging population. Its aim: to coordinate research efforts across the U.S. federal… Read »

Alzheimer’s Disease Part Two: Effecting Change – The Need for Validated Biomarkers of Risk and Response

We recently wrote about the continued, costly failure of Alzheimer’s disease drugs, often occurring in Phase 3 clinical development. Of 244 compounds tested from 2002 to 2012, only one gained approval. Today there are four compounds on the market for… Read »

Alzheimer’s Disease: Part One – Another One Bites the Dust

Alzheimer’s Disease: Part One – Another one bites the dust, but a possible glimmer of hope on the horizon   On February 14, Merck halted the Phase 3 trial of its Alzheimer’s disease drug candidate, verubecestat, after independent analysis showed that… Read »

Chan Zuckerberg Initiative Makes First Bio Research Awards

Last fall, the Chan Zuckerberg Initiative announced plans to invest $3 billion over 10 years in scientific efforts with an ambitious long-range aim to “cure, prevent or manage” all diseases. As a first part of that effort, they directed $600… Read »

Communicating Value

— Robert J. Easton, Co-Chairman, Bionest Partners   During the annual January gathering of the biopharma world in San Francisco this year, in-coming President Donald J. Trump put drug developers on notice and sent pharmaceutical and biotechnology stock prices plunging… Read »

The Orphan Drug Act: Successes and Challenges

By Alain J. Gilbert, Co-Chair, Bionest Partners   Rare and orphan diseases have grown dramatically as a focus of drug development since the passage of the Orphan Drug Act and the institution of other regulatory and financial incentives in both… Read »

1 8 9 10 11 12 14